Shares of Claris Lifesciences were trading higher by 11% to Rs 312 on the BSE, accompanied by heavy volumes, after an Economic Times report suggested that Cadila Healthcare has emerged as the front runner to acquire the generic sterile injectables business of the company. CLICK HERE TO READ FULL REPORT.
Earlier in February this year, in this regard, Claris Lifesciences had clarified that for the growth of the business, the company continues to explore and evaluate inorganic and strategic opportunities in various forms from time to time; nothing definitive in this regard has, however, happened.
The stock turned volatile after opening at Rs 323 on the BSE. It has touched high of Rs 331 and low of Rs 306 so far.
The trading volumes on the counter jumped more than 10-fold, with around 1.8 million shares already changing hands till 0958 hours as against an average 150,000 shares that were traded daily in the past two weeks on the BSE.
Meanwhile, shares of Cadila Healthcare were trading flat at Rs 1,750 on the BSE.
Earlier in February this year, in this regard, Claris Lifesciences had clarified that for the growth of the business, the company continues to explore and evaluate inorganic and strategic opportunities in various forms from time to time; nothing definitive in this regard has, however, happened.
The stock turned volatile after opening at Rs 323 on the BSE. It has touched high of Rs 331 and low of Rs 306 so far.
The trading volumes on the counter jumped more than 10-fold, with around 1.8 million shares already changing hands till 0958 hours as against an average 150,000 shares that were traded daily in the past two weeks on the BSE.
Meanwhile, shares of Cadila Healthcare were trading flat at Rs 1,750 on the BSE.
